Skip to main content
Top
Published in: Metabolic Brain Disease 1/2017

01-02-2017 | Original Article

DNA damage after chronic oxytocin administration in rats: a safety yellow light?

Authors: Daniela D. Leffa, Francine Daumann, Adriani P. Damiani, Arlindo C. Afonso, Maria A. Santos, Thayara H. Pedro, Renan P. Souza, Vanessa M. Andrade

Published in: Metabolic Brain Disease | Issue 1/2017

Login to get access

Abstract

Adjuvant therapy is a common therapeutic strategy used for schizophrenia management. Oxytocin has shown promising results as antipsychotic adjuvant in patients with schizophrenia. Although short-term clinical studies have indicated tolerability and no major side-effect manifestation, long-term studies remain needed. In this study, we investigated whether oxytocin chronic administration in rats may lead to brain DNA damage by comet assay. Our results suggest that 21 and 56-day treatment with once daily intraperitoneal oxytocin (0.1, 1.0 and 10.0 mg/kg) may cause substantial DNA damage in hippocampus. We have not found differences on body weight gain. Our findings also point that further clinical and preclinical studies evaluating oxytocin safety after chronic exposure are necessary.
Literature
go back to reference Boer GJ (1993) Chronic oxytocin treatment during late gestation and lactation impairs development of rat offspring. Neurotoxicol Teratol 15:383–389CrossRefPubMed Boer GJ (1993) Chronic oxytocin treatment during late gestation and lactation impairs development of rat offspring. Neurotoxicol Teratol 15:383–389CrossRefPubMed
go back to reference Bujanow W (1974) Letter: is oxytocin an anti-schizophrenic hormone? Can Psychiatr Assoc J 19:323PubMed Bujanow W (1974) Letter: is oxytocin an anti-schizophrenic hormone? Can Psychiatr Assoc J 19:323PubMed
go back to reference Collins A, Dusinská M, Franklin M, et al. (1997) Comet assay in human biomonitoring studies: reliability, validation, and applications. Environ Mol Mutagen 30:139–146CrossRefPubMed Collins A, Dusinská M, Franklin M, et al. (1997) Comet assay in human biomonitoring studies: reliability, validation, and applications. Environ Mol Mutagen 30:139–146CrossRefPubMed
go back to reference Feifel D, Reza T (1999) Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating. Psychopharmacology 141:93–98CrossRefPubMed Feifel D, Reza T (1999) Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating. Psychopharmacology 141:93–98CrossRefPubMed
go back to reference Gimpl G, Fahrenholz F (2001) The oxytocin receptor system: structure, function, and regulation. Physiol Rev 81:629–683PubMed Gimpl G, Fahrenholz F (2001) The oxytocin receptor system: structure, function, and regulation. Physiol Rev 81:629–683PubMed
go back to reference Huang H, Michetti C, Busnelli M, et al. (2014) Chronic and acute intranasal oxytocin produce divergent social effects in mice. Neuropsychopharmacology 39:1102–1114CrossRefPubMed Huang H, Michetti C, Busnelli M, et al. (2014) Chronic and acute intranasal oxytocin produce divergent social effects in mice. Neuropsychopharmacology 39:1102–1114CrossRefPubMed
go back to reference Mairesse J, Gatta E, Reynaert ML, Marrocco J, Morley-Fletcher S, Soichot M, Deruyter L, Camp GV, Bouwalerh H, Fagioli F, Pittaluga A, Allorge D, Nicoletti FMS (2015) Activation of presynaptic oxytocin receptors enhances glutamate release in the ventral hippocampus of prenatally restraint stressed rats. Psychoneuroendocrinology 62:36–46. doi:10.1016/j.psyneuen.2015.07.00 CrossRefPubMed Mairesse J, Gatta E, Reynaert ML, Marrocco J, Morley-Fletcher S, Soichot M, Deruyter L, Camp GV, Bouwalerh H, Fagioli F, Pittaluga A, Allorge D, Nicoletti FMS (2015) Activation of presynaptic oxytocin receptors enhances glutamate release in the ventral hippocampus of prenatally restraint stressed rats. Psychoneuroendocrinology 62:36–46. doi:10.​1016/​j.​psyneuen.​2015.​07.​00 CrossRefPubMed
go back to reference Miyamoto S, Miyake N, Jarskog LF, et al. (2012) Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 17:1206–1227. doi:10.1038/mp.2012.47 CrossRefPubMed Miyamoto S, Miyake N, Jarskog LF, et al. (2012) Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 17:1206–1227. doi:10.​1038/​mp.​2012.​47 CrossRefPubMed
go back to reference Moraes MCS, Neto JBC, Menck CFM (2012) DNA repair mechanisms protect our genome from carcinogenesis. Front Biosci 17:1362–1388CrossRef Moraes MCS, Neto JBC, Menck CFM (2012) DNA repair mechanisms protect our genome from carcinogenesis. Front Biosci 17:1362–1388CrossRef
go back to reference Singh NP, McCoy MT, Tice RR, Schneider EL (1988) A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 175:184–191CrossRefPubMed Singh NP, McCoy MT, Tice RR, Schneider EL (1988) A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 175:184–191CrossRefPubMed
go back to reference Tice RR, Agurell E, Anderson D, et al. (2000) Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 35:206–221CrossRefPubMed Tice RR, Agurell E, Anderson D, et al. (2000) Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 35:206–221CrossRefPubMed
Metadata
Title
DNA damage after chronic oxytocin administration in rats: a safety yellow light?
Authors
Daniela D. Leffa
Francine Daumann
Adriani P. Damiani
Arlindo C. Afonso
Maria A. Santos
Thayara H. Pedro
Renan P. Souza
Vanessa M. Andrade
Publication date
01-02-2017
Publisher
Springer US
Published in
Metabolic Brain Disease / Issue 1/2017
Print ISSN: 0885-7490
Electronic ISSN: 1573-7365
DOI
https://doi.org/10.1007/s11011-016-9885-z

Other articles of this Issue 1/2017

Metabolic Brain Disease 1/2017 Go to the issue